Reimagining Medicine

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Appendix Innovation: Clinical trials FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Group | Full year guidance Core Net Expenses expected to decrease by around 0.1bn vs. 2022 Financial Result Core Tax Rate Expected to be broadly in line vs. 2022 Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. 39 Investor Relations | Q2 2023 Results References Abbreviations FINANCIAL PROFILE NOVARTIS | Reimagining Medicine

View entire presentation